ArticleJournal of general internal medicine2026
GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisTo investigate whether the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in methadone-treated patients with opioid use disorder (OUD) and type 2 diabetes (T2D) is associated with improved cardiometabolic and mental health outcomes.
methodsThis retrospective population-based cohort study of adults (≥ 18 years) on methadone with both OUD and T2D (hemoglobin A
resultsAfter PSM, 1,157 patients (mean [SD] age, 57.3 [11.1] years; 577 females [49.9%]) were prescribed GLP-1 RAs. Use of GLP-1 RAs was associated with a decreased incidence of myocardial infarctions (hazard ratios [HR], 0.58; 95% CI, 0.41-0.80) and hypoglycemia (HR, 0.50; 95% CI, 0.33-0.77). Patients treated with GLP-1 RAs were more likely to enter OUD remission (HR, 1.75; 95% CI, 1.24-2.47) and fewer had episodes of major depression (HR, 0.71; 95% CI, 0.61-0.81), anxiety disorders (HR, 0.77; 95% CI, 0.67-0.88), and suicidal thoughts or behaviors (HR, 0.27; 95% CI, 0.16-0.47). CONCLUSIONS/
interpretationGLP-1 RA use in adults on methadone with both OUD and T2D was associated with lower rates of cardiometabolic and mental health complications. Randomized prospective trials are warranted to ascertain causality and clinical efficacy. RESEARCH-IN-CONTEXT: Methadone-treated patients with opioid use disorder (OUD) and type 2 diabetes mellitus (T2D) represent a particularly high-risk group for metabolic complications, yet the potential benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remain unclear. We examined whether GLP-1 RAs are associated with improved cardiometabolic and mental health outcomes among these patients. In the large, propensity score-matched cohort study of 2,314 methadone-treated patients with OUD and T2D, GLP-1 RAs use was associated with lower rates of myocardial infarctions, hypoglycemia, emergency department visits, and hospitalizations, along with higher rates of OUD remission and lower risks of opioid-related overdose, depression, and anxiety. Our findings indicate that GLP-1 RAs may mitigate cardiometabolic and mental health complications in methadone-treated patients with OUD and T2D, highlighting a potential therapeutic role for incretin-based drugs in opioid-related harm reduction in this high-risk population.
Indexed as
Identifiers
42151525What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.